Pancreatic Cancer: Progress and Challenges

Pancreatic Cancer: Progress and Challenges
+ show speakers and program
Monday, June 18
Keynote Presentation and Discussion: Pancreatic Cancer 2012
Do We Have the Tools and Knowledge to Defeat It?

7:30 p.m.-9:00 p.m.

Fatal attraction: A new story featuring the immune system and pancreatic cancer
Elizabeth M. Jaffee, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

The relentless pursuit approach
Daniel D. Von Hoff, Translational Genomics Research Institute, Phoenix, AZ
Opening Reception

9:00 p.m.-10:30 p.m.

Tuesday, June 19
Continental Breakfast and Meet the Expert Session 1

7:00 a.m.-8:00 a.m.
Session 1: Can We Diagnose Pancreatic Cancer Early?

Session Chairperson: Michael G. Goggins, Johns Hopkins Medical Institutes, Baltimore, MD
8:00 a.m.-10:00 a.m.

Early cancer detection with novel RNA biomarkers in circulating tumor cells
David T. Ting, Massachusetts General Hospital Cancer Center, Seattle, WA

Mouse to human search for pancreatic cancer biomarkers
Samir Hanash, Fred Hutchinson Cancer Center, Seattle, WA

Molecular imaging and biomarker discovery in pancreatic cancer
Kimberly A. Kelly, University of Virginia, Charlottesville, VA

10:00 a.m.-10:30 a.m.
Session 2: Can Pancreatic Cancer Be Avoided?

Session Chairperson: Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN
10:30 a.m.-12:30 p.m.

Obesity, autophagy, and inflammation: Common features in the pathogenesis and etiology of liver and pancreatic cancers
Michael Karin, University of California, San Diego, CA

Pancreatic cancer: Identifying those at high risk
Alison P. Klein, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

Familial pancreatic cancer surveillance: Outcomes and natural history of 100 patients over a decade
Teresa A. Brentnall, University of Washington, Seattle, WA
Poster Session A / Lunch

12:30 p.m.-3:00 p.m.
Session 3: How Does Pancreatic Cancer Develop?

Session Chairperson: Steven D. Leach, Johns Hopkins University School of Medicine, Baltimore, MD
3:00 p.m.-5:00 p.m.

The genomic landscape of pancreatic cancer: Diverse drivers of carcinogenesis?
Andrew V. Biankin, Garvan Institute of Medical Research, Sydney, Australia

Targeting cancer stem cells in pancreatic cancer
Diane M. Simeone, University of Michigan Hospital and Health Systems, Ann Arbor, MI

Exocrine plasticity and cancer
Matthias Hebrok, University of California, San Francisco, CA
Dinner on own / Free time

5:00 p.m.-7:30 p.m.
Session 4: Why Does Pancreatic Cancer Metastasize and Cause Cachexia and Pain?

Session Chairperson: Michael A. Hollingsworth, University of Nebraska Medical Center Eppley Cancer Center, Omaha, NE
7:30 p.m.-10:00 p.m.

EMT and dissemination precede pancreatic tumor formation
Ben Z. Stanger, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA

The role of pancreatic cancer stem cells in metastasis
Zeshaan A. Rasheed, Johns Hopkins University School of Medicine, Baltimore, MD

Cachexia, immune suppression, and the FAP+ stromal cell
Douglas Fearon, University of Cambridge, Cambridge, England

Wednesday, June 20
Continental Breakfast and Meet the Expert Session 2

7:00 a.m.-8:00 a.m.
Session 5: How Does the Tumor Microenvironment Influence Pancreatic Cancer?

Session Chairperson: Sunil R. Hingorani, Fred Hutchinson Cancer Research Center, Seattle, WA
8:00 a.m.-10:00 a.m.

Dynamic and reciprocal force regulation of tumor progression
Valerie M. Weaver, University of California San Francisco Medical Center, San Francisco, CA

Immune programming of the tumor microenvironment in pancreatic cancer
Lisa M. Coussens, OHSU Knight Cancer Institute, Portland, OR

Immune surveillance and CD40 therapy of pancreatic cancer in mice and humans
Robert H. Vonderheide, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA

10:00 a.m.-10:30 a.m.
Session 6: Can KRAS be Defeated?

Session Chairperson: Channing J. Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
10:30 a.m.-12:30 p.m.

Targeting K-ras for the treatment of pancreatic cancer
Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN

Functional genomics and KRAS-driven cancers
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

Targeting unique dependencies of RAS mutant tumors
Julian Downward, Cancer Research UK, London, England
Poster Session B / Lunch

12:30 p.m.-2:30 p.m.
Session 7: What Are the Promising Preclinical and Clinical Advances in Pancreatic Cancer?

Session Chairperson: Margaret A. Tempero, University of California, San Francisco, CA
2:30 p.m.-4:30 p.m.

Using patient-derived xenografts for personalized medicine in pancreas cancer
Manuel Hidalgo, Spanish National Cancer Center, Madrid, Spain

Altering drug delivery in pancreatic cancer: Development and clinical translation of smoothened inhibitors
Kenneth P. Olive, Columbia University Irving Comprehensive Cancer Center, New York, NY

How much gemcitabine reaches the target... and does it matter?
Duncan I. Jodrell, CRUK Cambridge Research Institute, Cambridge, England

4:30 p.m.-5:00 p.m.
Session 8: Are There New Ways to Prevent or Treat Pancreatic Cancer?

Session Chairperson: Anil K. Rustgi, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA
5:00 p.m.-7:00 p.m.

Autophagy, metabolism and pancreatic cancer
Alec C. Kimmelman, Dana-Farber Cancer Institute, Boston, MA

Regulation of metabolism to support tumor growth
Matthew G. Vander Heiden, Massachusetts Institute of Technology, Cambridge, MA

Microenvironment and pancreatic cancer
Roland M. Schmid, Klinikum rechts der Isar, Munich, Germany
Keynote Presentation and Discussion: Progress Ahead for Pancreatic Cancer

7:30 p.m.-10:00 p.m.

Targeting KRAS directly
Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Kras-directed anabolic processes in PDAC tumor maintenance
Ronald A. DePinho, University of Texas MD Anderson Cancer Center, Houston, TX

18 Jun - 21 Jun 2012

Lake Tahoe
United States of America
meeting website